ClinicalTrials.gg
RecruitingNCT07232069PRE-EMPTUpdated Nov 10, 2026

PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

A Phase 3 interventional study of Rosuvastatin 20 Mg Oral Tablet and Colchicine 0.5 MG Oral Tablet Once Daily in Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression and Prevention & Control, sponsored by Duke University. Recruiting at 23 sites in United States. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Duke University · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 10, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies testing rosuvastatin in Atherosclerosis — 1 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Atherosclerosis.

Planned enrollment
2nd of 24
1,500 · median 77
Started
2026
the only one that year
Phase 3
6 of 25
1 open now
Registered
25th of 25
by date
Lead sponsor
1 of 25
Duke University

Among the 25 studies testing rosuvastatin in Atherosclerosis, this one is the 2nd largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 3, and was the 25th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

1 of the 25 studies testing rosuvastatin in Atherosclerosis is open now, in 1 country.

By country, each count listing its studies:

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 30 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing rosuvastatin in Atherosclerosis, or all of them as a file.
02

Study summary

Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.

PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:

  1. A Screening Study - Participants will be assessed for plaque by one or both of these scans.

    • Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
    • Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
  2. A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.

    • Rosuvastatin 20 mg: a cholesterol-lowering medicine
    • Colchicine 0.5 mg: a medication that lowers inflammation

Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.

Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.

Read the detailed description

The PRE-EMPT trial will be a 2x2 factorial, double-masked, placebo-controlled randomized trial of the effects of high-intensity statin and low-dose colchicine, alone and in combination, on CCTA-defined Non-Calcified Coronary Plaque (NCCP) volume at 2 years. Participants found through the screening study with CAC 1-99, or through the known plaque pathway, will be eligible for the trial if they have NCCP without severe stenosis or any other exclusion criteria. Study drug will be delivered directly to participants' homes, lab samples will be self-collected at home, and all study visits will be virtual except the imaging visits (up to 3 over 2 years). The only in-person study activities will be the CAC scan, if applicable, and CCTA at baseline and 2 years. The investigators anticipate that this approach will be attractive to middle-aged, busy individuals who are otherwise healthy and asymptomatic. Importantly, all participants in PRE-EMPT will receive an mHealth lifestyle intervention designed to support behavioral modification, ensuring that all individuals benefit from evidence-based strategies for cardiovascular risk reduction.

03

Conditions studied

  • Coronary Artery Disease Risk Factors Multiple
  • Coronary Artery Disease Progression
  • Prevention & Control
  • Premature Atherosclerosis

Keywords

  • Prevention
  • Heart Disease Prevention
  • Family History of Heart Disease
  • At risk for heart disease
  • coronary artery calcium
  • non-calcified coronary plaque
04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 40-60 years; Men aged 30-50 years
  2. Willing and able to provide and comply with study procedures
  3. Smart phone user
  4. Use of highly effective by females with .
  5. CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC\<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)
  6. Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab

Exclusion criteria

Exclusion Criteria:

  1. Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)
  2. Current symptoms thought to be from CAD
  3. PREVENT ASCVD 10-year risk ≥5% (if known)
  4. Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or of 6.5% or greater. (if known)
  5. LDL-C ≥190mg/dL (most recent, if known)
  6. (if known)
  7. Severe liver disease or untreated infection (if known)
  8. Pregnancy, lactation or intending to become pregnant during the study period of 2 years
  9. \<45mL/min/1.73m2 (if known)
  10. or ALT >1.5x the (if known)
  11. >40kg/m2 or unable to have a CCTA scan for any reason
  12. Allergy to iodinated intravenous contrast or other to CCTA
  13. Current or previous use of lipid lowering therapy or colchicine
  14. Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.
  15. Systemic cancer undergoing active treatment
  16. PREVENT ASCVD 10-year risk ≥5%
  17. eGFR \<45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)
  18. Hemoglobin A1c ≥6.5% per baseline labs
  19. LDL-C ≥190mg/dL per baseline labs
  20. Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)
  21. Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)
  22. Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    rosuvastatin 20mg plus colchicine-matched placebo

    statin plus placebo (two pills once daily)

    Drug: Rosuvastatin 20 Mg Oral Tablet · Drug: Placebo

  • Experimental
    colchicine 0.5mg plus rosuvastatin-matched placebo

    anti-inflammatory plus placebo (two pills once daily)

    Drug: Colchicine 0.5 MG Oral Tablet Once Daily · Drug: Placebo

  • Experimental
    rosuvastatin 20mg plus colchicine 0.5mg

    statin plus anti-inflammatory (two pills once daily)

    Drug: Rosuvastatin 20 Mg Oral Tablet · Drug: Colchicine 0.5 MG Oral Tablet Once Daily

  • Placebo comparator
    placebo plus placebo

    Placebo and placebo (two pills once daily)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV.

    Plaque volume in mm3 in each group

    Time frame: 2 years

Secondary outcomes

  1. Number of participants with Drug Discontinuation

    Drug Tolerability outcome

    Time frame: Up to 2 years

  2. Overall drug treatment adherence

    Number of days on study drugs

    Time frame: Up to 2 years

  3. Safety events of special interest

    Number of safety events of special interest per group

    Time frame: Up to 2 years

  4. Total plaque volume

    Plaque volume in mm3 per group

    Time frame: Up to 2 years

  5. Low-attenuation plaque volume

    Low attenuated plaque volume in mm3 per group

    Time frame: Up to 2 years

  6. Calcified plaque volume

    Calcified plaque volume in mm3 per group

    Time frame: Up to 2 years

  7. Number of participants with stenosis

    Number of participants with stenosis per group

    Time frame: Up to 2 years

  8. Segment involvement score

    Average score per group

    Time frame: Up to 2 years

  9. Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition

    Number of participants with each plaque composition description per group

    Time frame: Up to 2 years

  10. Number of participants with High-risk plaque features (positive remodeling, spotty calcium, napkin ring sign)

    Number of participants with each plaque feature (high-risk) per group

    Time frame: Up to 2 years

  11. Change in LDL-C (low-density lipoprotein cholesterol)

    Time frame: Baseline to 2 years

  12. Change in non-HDL-C (high-density lipoprotein cholesterol)

    Time frame: Baseline to 2 years

07

Study locations

17 of 23 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35205, United States
    Recruiting
  • Cardiology Associates
    Mobile, Alabama 36608, United States
    Recruiting
    • Lynn Ward, RN BSN CCRC · Contactlynnward@cardassoc.com · 251-607-9797
    • Jason Cole, MD · Principal investigator
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
    Recruiting
  • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
    Los Angeles, California 90502, United States
    Recruiting
    • Sajad Hamal · Contactshamal@lundquist.org · 310-974-9336
    • Matthew Budoff, MD · Principal investigator
  • Wellstar Kennestone Hospital
    Hiram, Georgia 30141, United States
    Recruiting
  • University of Chicago
    Chicago, Illinois 60637, United States
    Recruiting
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
    Not yet recruiting
    • Prati Pratishruti, MBBS · Contactfpratis1@jhu.edu · 410-301-1245
    • Michael Blaha, MD · Principal investigator
  • Massachusetts General Hospital Brigham
    Boston, Massachusetts 02114, United States
    Recruiting
    • Pearl Lee, MSc · Contactplee23@mgh.harvard.edu · 617-721-7783
    • Michael Honigberg, MD · Principal investigator
  • Essentia Health
    Duluth, Minnesota 55805, United States
    Recruiting
  • Northern Westchester Hospital
    Mount Kisco, New York 10549, United States
    Not yet recruiting
  • New York University Langone
    New York, New York 10016, United States
    Recruiting
    • Harmony Reynolds, MD · ContactPREEMPT@nyulangone.org · 212-263-4320
    • Harmony Reynolds, MD · Principal investigator
  • Weill Cornell Medicine
    New York, New York 10021, United States
    Recruiting
  • Duke University Hospital
    Durham, North Carolina 27710, United States
    Recruiting
    • Niki Huffman · Contactniki.huffman@duke.edu · 919-681-6458
    • Nishant Shah, MD · Principal investigator
  • Wake Forest University, Advocate Health
    Winston-Salem, North Carolina 27157, United States
    Recruiting
  • Oregon Health and Sciences University
    Portland, Oregon 97239, United States
    Not yet recruiting
    • John Halvorson · Contacthalvorsj@ohsu.edu · 503-418-1679
    • Maros Ferencik, MD · Principal investigator
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
    Not yet recruiting
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • Karli Drewencki · Contactdrewenckikr2@upmc.edu · 412-647-2931
    • Anum Saeed, MD · Principal investigator
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
    Recruiting
    • Melissa Amitrano, MPH · Contactamitrano@musc.edu · 843-876-5009
    • Sheldon Litwin, MD · Principal investigator
  • Vanderbilt University
    Nashville, Tennessee 37203, United States
    Not yet recruiting
    • Gabriella Davies Thoppil, MD MPH · Contactg.thoppil@vumc.org · 615-421-1143
    • Deepak Gupta, MD · Principal investigator
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
    Recruiting
  • University of Virginia (UVA)
    Charlottesville, Virginia 22903, United States
    Recruiting
    • James Ingersoll · ContactWFC5KC@uvahealth.org · 434-982-1058
    • Todd Villines, MD · Principal investigator
  • Inova Health System
    Fairfax, Virginia 22031, United States
    Not yet recruiting
  • Marshfield Clinical Research Institute
    Marshfield, Wisconsin 54449, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2031, 60 months after the start.

Of 54 phase 3 interventional studies under Atherosclerosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 18, 2025
StartActual
Jul 21, 2026
Primary completionEst.
Jul 2031
CompletionEst.
Jul 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites changed recruiting status (10 now recruiting)
Show 10 sites
  • Massachusetts General Hospital Brigham · Boston, United StatesNot yet recruiting→Recruiting
  • New York University Langone · New York, United StatesNot yet recruiting→Recruiting
  • Wake Forest University, Advocate Health · Winston-Salem, United StatesNot yet recruiting→Recruiting
  • Houston Methodist Hospital · Houston, United StatesNot yet recruiting→Recruiting
  • University of Virginia (UVA) · Charlottesville, United StatesNot yet recruiting→Recruiting
  • Marshfield Clinical Research Institute · Marshfield, United StatesNot yet recruiting→Recruiting
  • University of Chicago · Chicago, United StatesNot yet recruiting→Recruiting
  • Essentia Health · Duluth, United StatesNot yet recruiting→Recruiting
  • University of Pittsburgh Medical Center · Pittsburgh, United StatesNot yet recruiting→Recruiting
  • Medical University of South Carolina (MUSC) · Charleston, United StatesNot yet recruiting→Recruiting
across 2 updates, Oct 7, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • University of Chicago · Chicago, United StatesNot yet recruiting→Recruiting
    • Essentia Health · Duluth, United StatesNot yet recruiting→Recruiting
    • University of Pittsburgh Medical Center · Pittsburgh, United StatesNot yet recruiting→Recruiting
    • Medical University of South Carolina (MUSC) · Charleston, United StatesNot yet recruiting→Recruiting
  2. Oct 7, 2026
    6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • Massachusetts General Hospital Brigham · Boston, United StatesNot yet recruiting→Recruiting
    • New York University Langone · New York, United StatesNot yet recruiting→Recruiting
    • Wake Forest University, Advocate Health · Winston-Salem, United StatesNot yet recruiting→Recruiting
    • Houston Methodist Hospital · Houston, United StatesNot yet recruiting→Recruiting
    • University of Virginia (UVA) · Charlottesville, United StatesNot yet recruiting→Recruiting
    • Marshfield Clinical Research Institute · Marshfield, United StatesNot yet recruiting→Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07232069
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Jul 21, 2026
Primary completion
Jul 2031 (estimated)
Completion
Jul 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Rachel Olson, Project Manager
Contact
rachel.e.olson@duke.edu
919-309-5544

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Colchicine

Start the discussion